140 related articles for article (PubMed ID: 30973677)
21. Do genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case report.
Lopes-Aguiar L; Visacri MB; Nourani CML; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Moriel P; Altemani JMC; Lima CSP
Medicine (Baltimore); 2015 Apr; 94(16):e578. PubMed ID: 25906090
[TBL] [Abstract][Full Text] [Related]
22. Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Maniglia MP; Russo A; Biselli-Chicote PM; Oliveira-Cucolo JG; Rodrigues-Fleming GH; -Maniglia JV; Pavarino ÉC; Goloni-Bertollo EM
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1637-1644. PubMed ID: 32592358
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.
Li F; Xie X; Ren X; Zhang J
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1183-91. PubMed ID: 27100737
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
25. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
26. Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk.
Cho CG; Lee SK; Nam SY; Lee MS; Lee SW; Choi EK; Park HJ; Kim SY
J Korean Med Sci; 2006 Dec; 21(6):1075-9. PubMed ID: 17179690
[TBL] [Abstract][Full Text] [Related]
27. Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation.
Ciaparrone M; Caspiani O; Bicciolo G; Signorelli D; Simonelli I; de Campora L; Mazzarella G; Mecozzi A; Pianelli C; Camaioni A; Catalano P; Pasqualetti P; Fabiano A; Radici M; Marmiroli L; Corsi DC
Oncology; 2015; 89(4):227-34. PubMed ID: 26066774
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Bohanes P; Rankin CJ; Blanke CD; Winder T; Ulrich CM; Smalley SR; Rich TA; Martensen JA; Benson AB; Mayer RJ; Cripps CM; Danenberg K; Makar KW; Zhang W; Benedetti JK; Lenz HJ
Clin Cancer Res; 2015 Apr; 21(7):1583-90. PubMed ID: 25589620
[TBL] [Abstract][Full Text] [Related]
29. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
[TBL] [Abstract][Full Text] [Related]
30. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of ERCC2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy.
Duran G; Cruz R; Aguín S; Barros F; Giráldez JM; Bernárdez B; Zarra I; López-López R; Carracedo Á; Lamas MJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):813-823. PubMed ID: 34309735
[TBL] [Abstract][Full Text] [Related]
35. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Liu YP; Ling Y; Zhang YP; Liu BR
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
[TBL] [Abstract][Full Text] [Related]
36. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer.
Pratesi N; Mangoni M; Mancini I; Paiar F; Simi L; Livi L; Cassani S; Buglione M; Grisanti S; Almici C; Polli C; Saieva C; Magrini SM; Biti G; Pazzagli M; Orlando C
Radiother Oncol; 2011 Jun; 99(3):356-61. PubMed ID: 21704413
[TBL] [Abstract][Full Text] [Related]
37. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
38. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Strom TJ; Naghavi AO; Trotti AM; Russell J; Kish JA; McCaffrey J; Otto KJ; Harrison LB; Caudell JJ
J Geriatr Oncol; 2017 Jan; 8(1):50-55. PubMed ID: 27720129
[TBL] [Abstract][Full Text] [Related]
39. Late toxicity after radical treatment for locally advanced head and neck cancer.
Taberna M; Rullan AJ; Hierro C; Navarro V; Vázquez S; Lozano A; Vilajosana E; Maños M; Marí A; Viñals J; Mesía R
Oral Oncol; 2015 Aug; 51(8):795-9. PubMed ID: 26051499
[TBL] [Abstract][Full Text] [Related]
40. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
